The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×

Sections

Identification and Assessment | Issues That May Bring AAS Users to Clinical Attention | Conclusion | References

Excerpt

The anabolic-androgenic steroids (AASs) are a family of hormones that includes the natural male hormone testosterone and hundreds of synthetic relatives of testosterone (Pope et al. 2014b). All AASs possess both anabolic (muscle-building) and androgenic (masculinizing) properties; it is equally correct to refer to these hormones simply as “androgens” (Kanayama et al. 2018a). Testosterone was first isolated in the 1930s, and numerous synthetic AASs were developed over the next decade. By the 1950s, athletes had discovered that AASs would allow them to achieve muscle gains far beyond those attainable by natural means, and AAS use spread rapidly throughout the elite athletic world (Kanayama and Pope 2018). However, it was not until the 1980s that AAS use began to emerge from elite athletics and into the general population. Now, between 3 and 4 million American men, and millions more worldwide, have used these drugs illicitly at some time (Pope et al. 2014a).

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.
  • Institutional Login
  • Sign in via OpenAthens
  • Register for access
  • Please login/register if you wish to pair your device and check access availability.

    Not a subscriber?

    Subscribe Now / Learn More

    PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

    Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).